Compass Therapeutics, Inc.

Compass Therapeutics announced positive survival and safety data from its Phase 2/3 COMPANION-002 study of tovecimig in combination with paclitaxel for biliary tract cancer. The study met its primary endpoint of overall response rate (18.0% vs 5.3%) and secondary endpoint of progression-free survival (4.7 months vs 2.6 months). The company anticipates FDA feedback in Q3 2026 for a potential Biologics License Application filing later this year. For the six months ended June 30, 2026, the company reported a net loss of $(43.471) million, with cash, cash equivalents, and marketable securities totaling $180 million, providing a runway into 2028.

Compass Therapeutics reported a net loss of $25.2 million for the second quarter of 2026, an increase from $19.9 million in the same period last year. The company maintained a strong cash position with $180 million in cash and marketable securities, providing a runway into 2028. Significant pipeline progress was highlighted, including expected FDA feedback on tovecimig Phase 2/3 data, an oral presentation at ESMO, active enrollment for CTX-8371 cohort expansions, initial dosing for CTX-10726 Phase 1, and planned initiation of CTX-471 Phase 2.

Compass Therapeutics announced that its abstract for the COMPANION-002 clinical trial has been accepted for an oral Proffered Paper presentation at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026. The presentation will highlight results from the randomized, controlled Phase 2/3 trial assessing tovecimig in combination with paclitaxel for patients with advanced biliary tract cancer. Dr. Nilofer Azad will present the findings on October 24, 2026.

Compass Therapeutics, Inc. updated its corporate presentation, highlighting positive data from the COMPANION-002 clinical study for Tovecimig in second-line biliary tract cancer. The study met its primary endpoint of overall response rate (ORR) and significantly improved progression-free survival (PFS). Despite overall survival (OS) being confounded by patient crossover, a subset analysis showed improved OS in crossover patients. The company plans an FDA meeting in Q3 2026 and a Biologics License Application (BLA) submission in Q4 2026, targeting potential approval and launch in 2027. The update also provided timelines for other pipeline assets, CTX-8371 and CTX-10726.

Compass Therapeutics, Inc.'s Board of Directors approved the adoption of Second Amended and Restated Bylaws, effective June 22, 2026. These new bylaws amend the existing ones to establish exclusive jurisdiction in the United States District Courts for the District of Delaware and District of Massachusetts for resolving any claims arising under the Securities Act of 1933. This update supersedes the company's previous bylaws dated July 17, 2020.

Compass Therapeutics, Inc. announced its participation in two investor events during May 2026. The company will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, and the 2026 Stifel Virtual Targeted Oncology Forum on May 20, 2026. Management will be available for one-on-one meetings at both events, and presentations will be archived online.

Compass Therapeutics announced positive Phase 2/3 study results for Tovecimig in biliary tract cancer, meeting its primary endpoint of overall response rate and showing significant improvement in progression-free survival. The company also received Orphan Drug Designation from the FDA for Tovecimig in BTC. For Q1 2026, Compass Therapeutics reported a net loss of $18.3 million, an increase from $16.6 million in Q1 2025, with cash and marketable securities of $195 million expected to fund operations into 2028.

Compass Therapeutics reported positive Phase 2/3 data for tovecimig in biliary tract cancer, demonstrating statistically significant improvement in progression-free survival and overall response rate, with plans for a BLA submission later this year. The company also provided updates on its pipeline, including an upcoming ASCO presentation for CTX-8371 and the initiation of a Phase 1 study for CTX-10726. For Q1 2026, Compass reported a net loss of $18.3 million and held $195 million in cash and marketable securities, providing a cash runway into 2028.

Compass Therapeutics reported a Q1 2026 net loss of $18.3 million and provided a corporate update. The company announced positive Phase 2/3 data for tovecimig in biliary tract cancer, including statistically significant improvement in progression-free survival and signals of a survival benefit, and plans to submit a Biologics License Application (BLA) later this year. Additionally, the Phase 1 study for CTX-8371 will be presented at ASCO 2026, and initial data for CTX-10726 is expected in Q4 2026. The company holds $195 million in cash, expected to fund operations into 2028.

Compass Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026, at 9:00 a.m. Eastern Time. Stockholders will vote on the election of two Class III directors, the ratification of CohnReznick LLP as the independent auditor for 2026, and advisory votes on executive compensation and its frequency. The company also highlighted recent executive appointments, including Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer in January 2026.